A trial record update dated August 12, 2026 lists an Expanded Access Program (EAP) for Deucrictibant Immediate-release, registered as NCT07759141. This entry relates to bradykinin, which remains classified as an unapproved research compound.
The listing status is recorded as "AVAILABLE," indicating that access through this program has been posted on ClinicalTrials.gov. No phase is specified for this record, consistent with its designation as an expanded access listing rather than a standard interventional trial phase.
The registry entry does not include information on trial results, safety findings, or efficacy outcomes. No dosing details, patient outcomes, or comparative data are provided in this update. The record reflects only the availability status and the associated title as posted on the specified date.
Readers should note that expanded access listings describe program availability rather than confirmed clinical benefit or risk. This update reports solely on the status change reflected in the ClinicalTrials.gov record for NCT07759141.
For additional background on bradykinin and its research classification, readers can consult the compound overview.